3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
3
Sponsor Class
OTHER
16
INDUSTRY
3
NIH
2
NETWORK
1
Study Type
Observational
2
Interventional
1
Sponsor
Cancer Type
Lymphoid
3
Conditions
Lymphoma, Non-Hodgkin
9
Lymphoma, Follicular
5
Lymphoma, Mantle-Cell
3
Lymphoma, Large B-Cell, Diffuse
2
Oncology Patients Receiving Chemotherapy
1
Lymphoma, B-Cell
1
Interventions
Rituximab
30
ibrutinib
26
Bendamustine Hydrochloride
18
Cyclophosphamide
17
acalabrutinib
14
fludarabine
13
Lenalidomide
11
zanubrutinib
10
venetoclax
9
Vincristine
7
Bortezomib
7
pirtobrutinib
5
brexucabtagene autoleucel
5
Prednisone
5
Doxorubicin
5
temsirolimus
4
parsaclisib
4
aflibercept
4
Gemcitabine
4
ublituximab
3
orelabrutinib
3
loncastuximab tesirine
3
idelalisib
3
ibritumomab tiuxetan
3
Sensitivity and Specificity
3
Antigens, CD19
3
tositumomab I-131
2
tazemetostat
2
pembrolizumab
2
fludarabine phosphate
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
INDUSTRY
×
Lymphoma, Mantle-Cell
×
ibritumomab tiuxetan
×
Clear all
NCT01448928
2021-10-01
ZEVALIN-DUI
Spectrum Pharmaceuticals, Inc
Completed
400 enrolled
NCT00505232
2012-01-02
LCM-04-02
CABYC
Phase 2
Completed
30 enrolled
NCT01479387
2011-11-24
ZEVALIN-SDUI
Bayer
Completed
72 enrolled